Immunotherapy and tumor microenvironment

Haidong Tang, Jian Qiao, Yang Xin Fu

Research output: Contribution to journalShort survey

56 Citations (Scopus)

Abstract

Recent exciting progress in cancer immunotherapy has ushered in a new era of cancer treatment. Immunotherapy can elicit unprecedented durable responses in advanced cancer patients that are much greater than conventional chemotherapy. However, such responses only occur in a relatively small fraction of patients. A positive response to immunotherapy usually relies on dynamic interactions between tumor cells and immunomodulators inside the tumor microenvironment (TME). Depending on the context of these interactions, the TME may play important roles to either dampen or enhance immune responses. Understanding the interactions between immunotherapy and the TME is not only critical to dissect the mechanisms of action but also important to provide new approaches in improving the efficiency of current immunotherapies. In this review, we will highlight recent work on how the TME can influence the efficacy of immunotherapy as well as how manipulating the TME can improve current immunotherapy regimens in some cases.

Original languageEnglish (US)
Pages (from-to)85-90
Number of pages6
JournalCancer Letters
Volume370
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Tumor Microenvironment
Immunotherapy
Neoplasms
Immunologic Factors
Drug Therapy

Keywords

  • CAR T-cell therapy
  • Checkpoint blockade
  • Chemokine
  • Cytokine
  • Tumor microenvironment
  • Tumor-infiltrating immune cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immunotherapy and tumor microenvironment. / Tang, Haidong; Qiao, Jian; Fu, Yang Xin.

In: Cancer Letters, Vol. 370, No. 1, 01.01.2016, p. 85-90.

Research output: Contribution to journalShort survey

Tang, Haidong ; Qiao, Jian ; Fu, Yang Xin. / Immunotherapy and tumor microenvironment. In: Cancer Letters. 2016 ; Vol. 370, No. 1. pp. 85-90.
@article{f56642e316094e55a73c6e6434cbd74c,
title = "Immunotherapy and tumor microenvironment",
abstract = "Recent exciting progress in cancer immunotherapy has ushered in a new era of cancer treatment. Immunotherapy can elicit unprecedented durable responses in advanced cancer patients that are much greater than conventional chemotherapy. However, such responses only occur in a relatively small fraction of patients. A positive response to immunotherapy usually relies on dynamic interactions between tumor cells and immunomodulators inside the tumor microenvironment (TME). Depending on the context of these interactions, the TME may play important roles to either dampen or enhance immune responses. Understanding the interactions between immunotherapy and the TME is not only critical to dissect the mechanisms of action but also important to provide new approaches in improving the efficiency of current immunotherapies. In this review, we will highlight recent work on how the TME can influence the efficacy of immunotherapy as well as how manipulating the TME can improve current immunotherapy regimens in some cases.",
keywords = "CAR T-cell therapy, Checkpoint blockade, Chemokine, Cytokine, Tumor microenvironment, Tumor-infiltrating immune cells",
author = "Haidong Tang and Jian Qiao and Fu, {Yang Xin}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2015.10.009",
language = "English (US)",
volume = "370",
pages = "85--90",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Immunotherapy and tumor microenvironment

AU - Tang, Haidong

AU - Qiao, Jian

AU - Fu, Yang Xin

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Recent exciting progress in cancer immunotherapy has ushered in a new era of cancer treatment. Immunotherapy can elicit unprecedented durable responses in advanced cancer patients that are much greater than conventional chemotherapy. However, such responses only occur in a relatively small fraction of patients. A positive response to immunotherapy usually relies on dynamic interactions between tumor cells and immunomodulators inside the tumor microenvironment (TME). Depending on the context of these interactions, the TME may play important roles to either dampen or enhance immune responses. Understanding the interactions between immunotherapy and the TME is not only critical to dissect the mechanisms of action but also important to provide new approaches in improving the efficiency of current immunotherapies. In this review, we will highlight recent work on how the TME can influence the efficacy of immunotherapy as well as how manipulating the TME can improve current immunotherapy regimens in some cases.

AB - Recent exciting progress in cancer immunotherapy has ushered in a new era of cancer treatment. Immunotherapy can elicit unprecedented durable responses in advanced cancer patients that are much greater than conventional chemotherapy. However, such responses only occur in a relatively small fraction of patients. A positive response to immunotherapy usually relies on dynamic interactions between tumor cells and immunomodulators inside the tumor microenvironment (TME). Depending on the context of these interactions, the TME may play important roles to either dampen or enhance immune responses. Understanding the interactions between immunotherapy and the TME is not only critical to dissect the mechanisms of action but also important to provide new approaches in improving the efficiency of current immunotherapies. In this review, we will highlight recent work on how the TME can influence the efficacy of immunotherapy as well as how manipulating the TME can improve current immunotherapy regimens in some cases.

KW - CAR T-cell therapy

KW - Checkpoint blockade

KW - Chemokine

KW - Cytokine

KW - Tumor microenvironment

KW - Tumor-infiltrating immune cells

UR - http://www.scopus.com/inward/record.url?scp=84949454830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949454830&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2015.10.009

DO - 10.1016/j.canlet.2015.10.009

M3 - Short survey

VL - 370

SP - 85

EP - 90

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -